Ear Nerve Stimulation for Hypertension: SCRATCH-HTN Trial

A small, self-administered ear device that delivers mild electrical pulses was tested in people whose blood pressure stayed high despite medication. In the SCRATCH-HTN trial, published in Hypertension, the device was safe, well tolerated, and practical for home use. However, it did not lower blood pressure significantly more than a sham device across all participants. A prespecified subgroup with more severe hypertension showed a promising reduction, but this needs confirmation.

What happened

Researchers at Queen Mary University of London led SCRATCH-HTN, funded by the National Institute for Health and Care Research (NIHR). The trial enrolled 63 people with uncontrolled hypertension. All were already taking at least one antihypertensive drug, yet their readings remained above recommended levels.

The intervention is called transcutaneous autonomic neuromodulation (tAN). The handheld device, made by Afferent Medical Solutions, uses two small clips placed on the tragus, the cartilage flap just in front of the ear canal. The clips deliver gentle electrical stimulation, and patients can use it themselves without visiting a clinic. The goal is to influence the autonomic nervous system, which automatically regulates heart rate, digestion, and blood pressure, without an invasive procedure.

Participants were randomized to active stimulation or a sham device. Everyone used their device for 30 minutes daily for the first two weeks, then once weekly for the next 10 weeks.

The results were mixed:

• Safety and usability: The treatment was safe and generally comfortable, and most participants followed the schedule.
• Primary comparison: Across the whole study population, there was no statistically significant difference in blood pressure change between the active and sham groups.
• Subgroup finding: In a prespecified subgroup analysis of participants who entered with more severe hypertension, active stimulation produced a greater blood pressure reduction than sham.

The chief investigator, Dr. Ajay Gupta, called the technology highly patient-acceptable and potentially cheap and scalable. He also acknowledged that the trial did not reach significance in the broad, unselected group. The source article does not report the exact blood pressure numbers, so we won't guess at them here.

Why it matters

Hypertension is a major driver of cardiovascular disease, heart attack, and stroke. Many patients remain above target even while taking medication. That gap is why researchers keep looking for add-on approaches, including device-based ones.

A non-invasive, home-based option would be attractive if it worked. The tragus is easy to reach and no surgery is involved. But this study is an early step, not proof of an effective treatment. The honest reading is that tAN looks feasible and safe, while its efficacy remains unproven, especially outside a possible severe-hypertension subgroup.

For a learner, the trial is also a useful case study in how autonomic physiology is translated into therapy, and in how to read a trial that is "negative overall but positive in a subgroup."

What to know for the USMLE

Here are the high-yield concepts this news touches on.

• Blood pressure = cardiac output × systemic vascular resistance. Sympathetic activation raises both: heart rate and contractility via β1 receptors, and vasoconstriction via α1 receptors.
• Baroreceptor reflex: Carotid sinus afferents travel via CN IX and aortic arch afferents via CN X to the nucleus tractus solitarius. A rise in pressure increases parasympathetic outflow and decreases sympathetic outflow. Neuromodulation aims to shift this autonomic balance.
• Renin–angiotensin–aldosterone system (RAAS): Sympathetic stimulation of β1 receptors on juxtaglomerular cells increases renin release, which links the nervous system to long-term volume and pressure control.
• Resistant hypertension is the textbook term for blood pressure above goal despite three agents of different classes, including a diuretic, at optimal doses. Note that SCRATCH-HTN enrolled people with uncontrolled hypertension on at least one drug, which is a broader group than strictly defined resistant hypertension.
• Before calling it resistant, exclude pseudoresistance: nonadherence, white-coat effect, improper cuff size or technique, and interfering drugs (NSAIDs, decongestants, oral contraceptives).
• Secondary causes to remember: primary aldosteronism (low renin, hypokalemia), renal artery stenosis, obstructive sleep apnea, chronic kidney disease, pheochromocytoma, and Cushing syndrome.
• Standard drug classes: ACE inhibitors/ARBs, calcium channel blockers, thiazide-like diuretics, and mineralocorticoid receptor antagonists such as spironolactone, a classic add-on in resistant disease.
• Anatomy tip: The ear's sensory supply is mixed. The tragus is typically described as receiving the auriculotemporal nerve (a branch of V3), and parts of the ear, such as the concha, receive the auricular branch of the vagus nerve. The source does not say which nerve the device targets, so don't assume it is the vagus.
• Trial-design concepts: a sham control helps separate true treatment effect from the placebo effect, which is especially important for BP outcomes. A prespecified subgroup analysis is more credible than a post hoc one, but it is still hypothesis-generating when the main result is null.

Limitations

• Small trial: With 63 participants, the study had limited power. Subgroup analyses divide an already small sample further, which makes the estimates imprecise.
• Null primary comparison: The overall result was not statistically significant. A positive subgroup does not override that.
• Subgroup caution: Even prespecified subgroup findings can be due to chance, particularly when several subgroups are tested. The authors say the finding needs confirmation in larger studies.
• Short follow-up: The treatment period was 12 weeks. Durability of any effect is unknown.
• Unclear mechanism: The article says the aim is to influence autonomic regulation, but it does not establish how or whether that actually occurred.
• Missing details: The source material doesn't give effect sizes, how BP was measured, or the definition of "more severe hypertension." We can't evaluate these points from the summary alone.
• Not an individual recommendation: The device is experimental. Nothing here is guidance for any patient's treatment.

FAQ

Does ear nerve stimulation lower blood pressure?

Not convincingly yet. In SCRATCH-HTN, active stimulation did not significantly outperform a sham device across all participants. A greater reduction was seen in a subgroup with more severe hypertension, but that finding requires confirmation.

Is transcutaneous autonomic neuromodulation safe?

In this trial, it was reported as safe and generally comfortable, and most participants followed the schedule. With only 63 participants over a short period, however, rarer or longer-term effects can't be excluded.

Is this the same as resistant hypertension?

Not exactly. Participants had uncontrolled blood pressure while taking at least one medication. Resistant hypertension has a stricter textbook definition, usually uncontrolled blood pressure on three drugs including a diuretic, after pseudoresistance is excluded.

Key takeaways

• SCRATCH-HTN (63 patients, sham-controlled) found tAN safe and practical at home, but no significant overall blood pressure benefit versus sham.
• A prespecified subgroup with more severe hypertension showed a larger reduction, which is hypothesis-generating and needs larger trials.
• For USMLE, connect this to autonomic BP regulation (baroreflex, sympathetic tone, RAAS), the definition and workup of resistant hypertension, and how to critique subgroup analyses and sham-controlled designs.